Version October 2024
Diagnostic imaging:
Children ≥12 years and Adolescents: Oral inhalation: 75 to 100 mL Dose Equivalent (DE) via the entire contents of one dose delivery bag. Do not use dose delivery bag if the DE is <75 mL; DE of >100 mL is acceptable.
Note: DE is the total volume (mL) of 100% hyperpolarized, 100% isotopically enriched xenon Xe 129 that would provide the equivalent total Xe 129 magnetization (MRI) signal. DE is measured by the HPX Polarization Measurement Station and is defined by the following formula:
DE = (total volume xenon gas) × (fraction of xenon Xe 129 isotopic enrichment in the xenon gas) × (fraction of hyperpolarization)
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
(For additional information see "Xenon Xe-129 hyperpolarized: Drug information")
Diagnostic imaging: Inhalation: Target dose: 75 to 100 mL dose equivalent (DE) (entire contents of one dose delivery bag); minimum dose: 75 mL DE; >100 mL DE is acceptable.
DE is the volume (mL) of 100% hyperpolarized, 100% isotopically enriched xenon XE 129 that provides the equivalent total X2 129 magnetization (MRI signal) and is defined by the following formula:
DE = (total volume xenon gas) × (fraction of xenon XE 129 isotopic enrichment in the xenon gas) × (fraction of hyperpolarization)
where volume of xenon gas is 250 to 750 mL, the fraction of xenon Xe 129 isotropic enrichment is >80% and the mean fraction of hyperpolarization is ≥38% to 54% at the completion of polarization of 250 mL of xenon gas.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.
1% to 10%:
Nervous system: Dizziness, headache
Respiratory: Oropharyngeal pain
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Hypoxia: Transient hypoxemia may occur; treat as clinically indicated.
Other warnings/precautions:
• Appropriate use: Has not been evaluated for use with lung perfusion imaging. Concomitant supplemental oxygen may decrease image quality due to depolarization; withhold oxygen inhalation for 2 breaths prior to xenon Xe 129 hyperpolarized inhalation and resume immediately following imaging breath hold.
Transient heart rate elevation, numbness, and tingling have been reported with use in pediatric patients 6 to 18 years of age.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Gas, Inhalation:
Xenoview: 1% (1 ea)
No
Gas (Xenoview Inhalation)
1% (per each): $62,400.00
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral inhalation: Administer within 5 minutes of dose equivalent measurement; refer to the HPX Hyperpolarization System Operator's Manual and/or manufacturer labeling for detailed administration instructions.
Inhalation: Administer by inhalation within 5 minutes of dose equivalent measurement; refer to the HPX Hyperpolarization System Operator’s Manual and manufacturer labeling for detailed administration instructions.
Store at 20°C to 25°C (68°F to 77°F) for ≤5 minutes after final dose equivalent measurement; discard 60 minutes after filling dose delivery bag. Store xenon Xe 129 gas blend at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
Contrast agent for use with MRI for evaluation of lung ventilation (FDA approved in ages ≥12 years and adults). Note: Use in patients <12 years of age is not approved because the dose cannot be accurately administered.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
There are no known significant interactions.
Due to minimal absorption following inhalation, maternal use is not expected to result in fetal exposure.
Oxygen saturation; heart rate; signs or symptoms of hypoxemia.
Contrast agent that when inhaled is distributed throughout the ventilated lung and can be used for imaging with a multi-nuclear capable MRI scanner; hyperpolarized xenon Xe 129 nuclei are directly detected by a Xe 129 MRI coil.
Duration: Ventilated areas of the lungs; small amount into pulmonary vessels leading to distal organ distribution. Solubility is greater in fatty tissue than aqueous tissue or body compartments (eg, plasma).
Half-life elimination: 14.5 seconds (75% Xe/25% N2 gas mixture); 14.3 seconds (25% Xe/75% N2 gas mixture).
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
